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Abstract
Purpose: There are conflicting reports regarding the function of EFEMP1 in different cancer types. In this study, we
sought to evaluate the role of EFEMP1 in malignant glioma biology.
Experimental Design: Real-time qRT-PCR was used to quantify EFEMP1 expression in 95 glioblastoma multiforme
(GBM). Human high-grade glioma cell lines and primary cultures were engineered to express ectopic EFEMP1, a
small hairpin RNA of EFEMP1, or treated with exogenous recombinant EFEMP1 protein. Following treatment,
growth was assayed both in vitro and in vivo (subcutaneous (s.c.) and intracranial (i.c.) xenograft model systems).
Results: Cox regression revealed that EFEMP1 is a favorable prognostic marker for patients with GBM. Over-
expression of EFEMP1 eliminated tumor development and suppressed angiogenesis, cell proliferation, and VEGFA
expression, while the converse was true with knock-down of endogenous EFEMP1 expression. The EFEMP1
suppression of tumor onset time was nearly restored by ectopic VEGFA expression; however, overall tumor growth
rate remained suppressed. This suggested that inhibition of angiogenesis was only partly responsible for EFEMP1’s
impact on glioma development. In glioma cells that were treated by exogenous EFEMP1 protein or over-expressed
endogenous EFEMP1, the EGFR level was reduced and AKT signaling activity attenuated. Mixing of EFEMP1 protein
with cells prior to s.c. and i.c. implantations or injection of the protein around the established s.c. xenografts, both
significantly suppressed tumorigenicity.
Conclusions: Overall, our data reveals that EEFEMP1 suppresses glioma growth in vivo, both by modulating the
tumor extracellular microenvironment and by altering critical intracellular oncogenic signaling pathways.
Background
Fibulins are a seven-member family of secreted glyco-
proteins, which are characterized by repeated epidermal
growth-factor-like domains and a unique C-terminal
structure [1]. Recent studies exploring the role of fibu-
lins in cancer biology have yielded conflicting results.
Different members of the fibulin family have been
shown to demonstrate either tumor-suppressive or
oncogenic activity [2]. Paradoxically, an individual fibu-
lin can also demonstrate either tumor-suppressive or
oncogenic behavior tied to tissue-specific expression. An
example of this phenomenon is fibulin 3, officially
named EGF-containing fibulin-like extracellular matrix
protein 1 (EFEMP1).
In support of a possible tumor-suppression role,
EFEMP1 was discovered to have an anti-angiogenic func-
tion via suppression of endothelial cell sprouting [3].
There are additional reports showing that: (A) tumorigeni-
city of fibrosarcoma cells was inhibited by EFEMP1 over-
expression, (B) reduced EFEMP1 expression and/or
EFEMP1 promoter methylation occurs in lung, liver,
breast, prostate, and nasopharyngeal carcinomas [4-9], and
(C) a decrease in EFEMP1 expression in hepatocellular
and nasopharyngeal carcinoma is correlated with a worse
* Correspondence: yihongz@uci.edu
1Department of Biological Chemistry, University of California Irvine, 5171
California Ave., Suite 150, Irvine, CA (92697), USA
Full list of author information is available at the end of the article
Hu et al. Molecular Cancer 2011, 10:123
http://www.molecular-cancer.com/content/10/1/123
© 2011 Hu et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.prognosis [5,9]. In contrast, a potential cancer-promoting
function of EFEMP1 was implied in two clinical studies; in
one study, the level of EFEMP1 expression was correlated
to poor prognosis for cervical cancer [10], while the other
study demonstrated EFEMP1 o v e r - e x p r e s s i o ni nb r e a s t
carcinoma [11]. In addition, pancreatic adenocarcinoma
cells, EFEMP1 over-expression was shown to promote
xenograft formation [12]. The potentially variable tissue-
specific effects of EFEMP1 on cancer patient prognosis are
reflected in the corresponding tissue-derived cancer in
vitro assays, revealing the ability of EFEMP1 to either acti-
vate [13] or suppress [9] AKT signaling activity in pan-
creatic or nasopharyngeal carcinoma cell lines,
respectively.
In glioma cells, EFEMP1 was shown to enhance in
vitro substrate-specific cell adhesion and promote cell
motility and dispersion [14]. However, to date, there has
been no in vivo study of EFEMP1 effects on human
glioma biology. Results from microarray analyses
revealed that EFEMP1 is up-regulated by transcription
factor PAX6 - a tumor suppressor in malignant gliomas
[15-19]. As a protein functioning in the extracellular
milieu, given its potential tumor-suppressive role, there
is an interest to develop EFEMP1 into a new therapeutic
agent for patients with malignant glioma. We thus car-
ried out an in-depth study of EFEMP1 expression as a
prognostic marker in the most malignant grade of
glioma, glioblastoma multiforme (GBM). We utilized
various human malignant glioma cell lines and primary
cultures to examine the mechanisms of EFEMP1 tumor
suppression. Most importantly we demonstrated an in
vivo tumor suppression effect of EFEMP1 in both sub-
cutaneous and intracranial xenograft models.
Materials and methods
GBM cDNA samples, patient follow-up, and gene
expression quantification
We included 95 glioblastoma multiforme (GBM) cDNA
samples and patients’ overall survival data from our pre-
viously described glioma prognosis project [20]. cDNA
samples of human glioma cell cultures and subcuta-
neous (s.c.) xenografts were made from 2-3 μgt o t a l
RNA using superscript reverse transcriptase II (Invitro-
gen). Real-time qRT-PCR were carried out in a StepOne
real-time PCR instrument (Applied Biosystems, Foster
City) using
AqRT-PCR Standard-1020 (for EFEMP1, VEGFA)a n d
Standard-1057 (for KDR) and primer sets for the mar-
ker/target gene and reference gene (ACTB), provided by
Ziren Research LLC (Irvine, CA).
Glioma cell lines and primary cultures
High-grade glioma cell lines U251HF, SNB19 and
LN229 were gifts from A. Yung’s lab at M.D. Anderson
Cancer Center [17]. Glioma primary cultures were
derived from patient glioma specimens requested and
cultured according to approved IRB and IBC protocols.
Single-cell suspensions were prepared by digesting
tumor pieces with 0.05% Trypsin-EDTA for 30-45 min
followed by mechanical dissociation (passing through a
glass pipette until smooth) in cold tissue-dissociation
buffer (DMEM/F12 containing 0.10 mg/ml DNase and
10% fetal bovine serum). Dissociated cells were cultured
in DMEM/F12 medium supplemented with 5% bovine
serum in collagen-coated (2 μg/cm
2)c u l t u r ep l a t e s .A l l
cultures were grown at 37°C in a tissue culture incuba-
tor with 5% CO2.
Plasmid and lentiviral vectors, transfection and infection,
and EFEMP1 protein
Full-length EFEMP1 cDNA of protein-coding region by
all three transcription variants (NM_001039348,
NM_001039349, NM_004105) was PCR-amplified using
a5 ’ primer that contains a Hind III site and a 3’ primer
with or without an octapeptide FLAG in front of the
stop codon. The PCR fragment was then cloned into
pcDNA3.1+ and verified by sequencing. The stable
EFEMP1-transfected clones of U251HF were established
via transfection of plasmid DNA of EFEMP1/pcDNA3.1
+o rE F E M P 1 - C F( C-terminal FLAG tag)/pcDNA3.1+.
Positive clones were verified by real-time qRT-PCR and
immunoblotting with FLAG antibody (Figure 1).
Plasmid constructs of three VEGFA isoforms, VEGF-
121, VEGF-165, VEGF-189, and control-vector LacZ
were kindly provided by Dr. Shi-Yuan Cheng [21]. Each
plasmid construct was transfected into the EFEMP1-
transfected clone (EFEMP1c6) of U251HF, and subjected
to dual selection with neomycin (400 mg/ml) and hygro-
mycin B (75 mg/ml) for a duration of 2-3 weeks. Lenti-
viral vectors pGIPZ-shEFEMP1 (expressing a small
hairpin RNA of EFEMP1) and pGIPZ-Empty were pro-
cured from Open Biosystems (Huntsville, AL). Infectious
lentivirus was produced by co-transfection of the lenti-
viral vector construct with packaging plasmid psPAX2
and envelope plasmid pCMV-VSVG in HEK-293T cells,
following the manufacturer’s protocol. The infected
glioma primary cultures were selected for 1-2 weeks in
culture medium containing 1.25 μg/ml puromycin prior
to analysis.
Human recombinant EFEMP1 protein was from
Abnova (Walnut, CA). Proteinw a sd i s s o l v e di nv e h i c l e
(50 mM Tris-HCl, 10 mM reduced Glutathione, pH =
8.0).
In vitro cell and in vivo tumor growth assays
We used an MTT assay to measure glioma cell prolif-
eration in vitro previously described, which provides
results consistent with viable-cell counting [18]. For
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Page 2 of 12formation of intracranial (i.c.) xenografts, cells (1 × 10
5
/3 μl DMEM/F12) were injected into the frontal lobe of
4-6 week old female nude mice (stain NCrNu-M, Taco-
nic, Hudson, NY), using a Harvard Apparatus Model 11
Plus Syringe Pump and a mouse stereotactic frame.
Mice were observed daily until moribund signs (hunch-
back and motionless) appeared, and were terminated the
following day (which was recorded as the survival date).
For formation of subcutaneous (s.c.) xenografts, cells
(2.5 or 1 × 10
6 cells/50 μl DMEM/F12) were subcuta-
neously injected into nude mice anterior to their right
and left thighs on both sides. Tumor measurements
were taken every 3-4 days after implantation, and tumor
volume was calculated using the formula V = (L*W
2)/2
(L, length; W, width).
Modulated imaging (MI) and magnetic resonance imaging
(MRI)
Mice with s.c. xenografts were subjected to modulated
imaging as described previously [19], which provides
quantitative measures of the in vivo concentrations of
oxyhemoglobin (OHb), deoxyhemoglobin (RHb) and
total hemoglobin (THb). THb is an index of angiogen-
esis, while oxygen saturation (StO2), the ratio of OHb to
THb, reflects tumor-cell metabolic activity.
Mice with i.c. xenografts were anesthetized using 50
mg/kg sodium pentobarbital, and transported inside
sterile cylindrical mouse-isolation containers that have
small exhaust holes that allow the administration of gas
anesthesia during the imaging studies. Isoflurane was
used for anesthesia during imaging. MR images were
acquired using a 7T small animal imaging system. T2-
weighted images were acquired using a 2D spin-echo
pulse sequence with the following parameters: TR = 3.5
s, TE = 50 ms, matrix size = 256 × 256, FOV = 30 mm,
slice thickness = 0.8 mm, NEX = 2. T1-weighted images
were acquired using a 2D spin-echo pulse sequence
with the following parameters: TR = 350 ms, TE = 10
ms, matrix size = 256 × 256, FOV = 30 mm, slice thick-
ness = 1 mm, NEX = 6. 0.2 mmol/kg of gadodiamide
Figure 1 EFEMP1 over-expression suppressed U251HF cell growth in vivo not in vitro. A, FLAG immunoblot of conditioned-medium (CM)
proteins from cell cultures of U251HF (p) and stable transfectants of FLAG-tagged EFEMP1. B&C , real-time qRT-PCR quantification of EFEMP1
mRNA levels in U251HF transfected with FLAG-tagged or untagged EFEMP1 constructs, normalized to GAPDH, and compared with untransfected
cell arbitrarily set to unity. D, MTT detection of cell in vitro growth speed. E, Kaplan-Meier survival curves for mice after i.c. implantation with
U251HF and its EFEMP1 transfectants.
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MR imaging. SMIS NMR software was used to calculate
the dimensions of the brain tumor in the i.c. xenograft
mice. Tumor volume measurement (Volume = Area ×
Depth × 1/2 in mm
3) involved calculating the area of
the image with largest tumor size by the “free hand”
ROI option in the software, which highlights the peri-
meter of the tumor in that slice. Depth was calculated
by multiplying the number of slices where visible tumor
was seen by 0.8 (thickness of each slice).
Immunofluorescence assay
Immunofluorescence of s.c. xenograft cryosections (10
μm) was carried out using PECAM-1 [CD31] (1:300,
Millipore Corp, Temecula, CA) and Ki67 (1:1000,
Abcam Inc, Cambridge, MA) primary antibodies. Fluros-
cein anti-rat IgG (H+L) and rhodamine anti-rabbit IgG
(H+L) were used as secondary antibodies. The fluores-
cence signals were detected using IMAGEJ 1.42 (NIH-
IMAGE) which provide counting (blood vessel number)
and total area (size of total blood vessels in a micro-
scope image). The blood vessel density (BVD) was com-
puted based on the vessel number per image of 1.02
mm
2 for 4-6 areas from three s.c. xenografts. For the in
vivo tumor-cell proliferation index (PI), information was
presented as the percentage of positive Ki67-staining
cells to the total number of DAPI-staining nuclei.
Western blotting, VEGFA enzyme immunometric assays
Conditioned medium (CM) was harvested from 48-hour
cell cultures and spun through Vivaspin 20 columns to
increase protein concentration. The TnT T7 Quick
Transcription/Translation System (Promega, Madison,
WI) was used to synthesize EFEMP1-FLAG protein,
which was used as a positive control in immunoblotting
for detection of EFEMP1-FLAG using a FLAG M2
monoclonal antibody (Sigma, St. Louis, MO, 1:1000
dilution). Proteins of cell culture and s.c. xenografts
were extracted in radioimmunoprecipitation assay
(RIPA) buffer containing 1X protease inhibitor cocktail
(Roche) with a glass homogenizer (for tumors), and sub-
jected to western blotting. Antibodies used include Fibu-
lin-3 (mab3-5) from Santa Cruz Biotechnology (Santa
Cruz, California), Actin from EMD Bioscience (San
Diego, CA), EGFR, AKT, and pAKT(Ser 473) from Cell
Signaling Technology (Danvers, MA). A human VEGFA
enzyme immunometric assay (ELISA) kit (Assay
Designs, Ann Arbor, MI) was used for quantification of
VEGFA isoform VEGF165 in tumor protein extract
according to the manufacturer’s instructions.
Antibody array
Protein microarray analysis were carried out using a
phospho-specific antibody microarray (Full Moon
Biosystems, Inc) according to the manufacturer’sp r o t o -
col. Briefly, 100 μg of cell lysate in 50 μLo fr e a c t i o n
mixture were labeled with 1.43 μL biotin in 10 μg/μLN ,
N-dimethyformamide. The resulting biotin-labeled pro-
teins were diluted 1:20 in coupling solution before
applying to the array for conjugation. The antibody
microarray was blocked with blocking solution for 30
min at room temperature, rinsed with Milli-Q-grade
water for 3 min, dried with compressed nitrogen, and
incubated with the biotin-labeled cell lysates at 4°C
overnight. The slide was washed twice with 60 mL of 1×
wash solution for 10 min. The conjugated-labeled pro-
tein was detected using Cy3-streptavidin. The images
and data were acquired on Axon GenePix scanner.
Phospho-specific antibody activities were compared by
corresponding total protein.
Statistical analysis
Data was examined prior to analysis for adherence to
distributional assumptions, and transformed if necessary
via logarithmic transformation to stabilize variance.
One-way ANOVAs with standard post hoc comparisons
were used to identify effects of EFEMP1 on cell MTT
value, tumor weight, blood-vessel density, proliferation
index, and gene expression between multiple stable
transfectants and the untransfected cells. Mixed-models
ANOVAs were used to analyze longitudinally measured
tumor volumes for effects due to knock-down of
EFEMP1 using shRNA and rescue by exogenous
EFEMP1 protein. Group average tumor volumes ± stan-
dard errors (SEs) were calculated as the grand mean of
average volumes across all time points. Doubling times
and SEs were calculated from log2-scale growth rates
and their SEs by inversion and delta method, respec-
tively. Overall survivals in mice implanted i.c. with dif-
ferent EFEMP1 transfectants were estimated via Kaplan-
Meier curves and compared for differences via logrank
test. Overall survivals in humans with GBM were corre-
lated with EFEMP1 expression in their tumor cDNA
samples by means of Cox regression, with the univariate
predictor being the log10-scaled ratio of EFEMP1 vs.
ACTB mRNA as measured by absolute real-time qRT-
PCR. SAS versions 9.1.3 and 9.2 (The SAS Institute,
Cary, NC) were used for all analyses.
Results
EFEMP1 expression in GBM is related to a longer overall
survival of patients
We investigated the prognostic value of EFEMP1 based
on its expression in 95 GBM specimens. The mRNA
levels of EFEMP1 and reference gene ACTB were quan-
tified using absolute real-time qRT-PCR [22]. The
log10-transformed ratio of EFEMP1 to ACTB was used
a st h eu n i v a r i a t ep r e d i c t o ri naC o xr e g r e s s i o nw i t h
Hu et al. Molecular Cancer 2011, 10:123
http://www.molecular-cancer.com/content/10/1/123
Page 4 of 12overall survival time as outcome variable. The parameter
estimate for EFEMP1 expression in GBM was -0.182
[likelihood-ratio P = 0.097], equivalent to a 17%
decrease in mortality with each 10-fold increase in the
EFEMP1/ACTB ratio, which suggests that the overall
survival time increases as EFEMP1 expression levels
increase. This finding suggested that EFEMP1 may be
important to study for its tumor suppressor function in
GBM.
EFEMP1 suppresses tumorigenicity of human high grade
glioma cell line U251HF
We started an investigation of EFEMP1 using the
human malignant glioma cell line U251HF, which is
highly tumorigenic and forms GBM-like infiltrating
necrotic tumors in i.c. xenograft model systems [17].
Since EFEMP1 is a secreted protein within the extracel-
lular matrix compartment, we initially determined the
ability of transfected cells to secret a FLAG-tagged
EFEMP1 in culture medium. As shown in Figure 1A,
western blotting of proteins secreted by cells showed
FLAG-tagged EFEMP1. Secreted protein levels corre-
lated with EFEMP1 mRNA expression quantified by
real-time qRT-PCR (Figure 1B).
We focused the functional assays on the U251HF cell
line transfected with un-tagged EFEMP1 (EFEMP1c2:9-
fold increase of EFEMP1 mRNA, EFEMP1c6: 15-fold
increase of EFEMP1 m R N A ,F i g u r e1 C ) .A ss h o w nF i g -
ure 1D, there was no obvious effect of EFEMP1 expres-
sion on in vitro cell growth, nor were there any
morphological changes (data not shown). However,
EFEMP1 over-expression dramatically suppressed
tumorigenicity (Figure 1E). The survival of mice after i.
c. implantation of the EFEMP1-transfected cells was sig-
nificantly prolonged (EFEMP1c6) and in some instances,
animals were completely free of tumor (EFEMP1c2). As
expected, animals implanted with the un-transfected
parental cells (U251HF) all died of their tumor between
24-46 days post-implantation. Two of the five mice
implanted with EFEMP1c6 cells died between 57-60
days, one died at 90 days, while the remaining two sur-
vived beyond 95 days after implantation. A repeat of the
i.c. implantation experiment confirmed EFEMP1-
mediated suppression of U251HF tumorigenicity in the
in vivo i.c. xenograft model system.
EFEMP1 suppresses VEGFA-induced angiogenesis
The strikingly different effect of EFEMP1 on glioma-cell
growth potential in vitro and in vivo suggested involve-
ment of tissue or environmental factors, and we strongly
suspected angiogenesis to play a key role. To evaluate
this possibility, we implanted the same groups of cells
tested for tumorigenicity in i.c. locations into subcuta-
neous (s.c.) locations of nude mice. This allowed for the
dual monitoring of tumor growth speed and measure-
ments reflecting the blood uptake and consumption by
tumors in live animals using modulated imaging [19].
EFEMP1 over-expression in U251HF cells led to
tumor growth suppression of s.c. tumors just as it had
for i.c. tumors. EFEMP1c2 failed to form any tumors in
3 months, while tumor size at day 24 for EFEMP1c6
was 12% of the average tumors derived from the paren-
tal cells (Figure 2A). Results from modulated imaging
revealed that the tumors with EFEMP1 over-expression
had significantly lower levels of both OHb and RHb
compared to parental cell-derived tumors, resulting in
significantly lower levels of THb. No significant differ-
ence in StO2 was observed (Figure 2B). This data sug-
gested that increasing EFEMP1 expression in U251HF
inhibited angiogenesis but not oxygen-dependent meta-
bolic activity.
Immunofluorescence detection of mouse endothelial
cell marker CD31 antigen in s.c. tumor sections revealed
a significant loss in number (average 41%) as well as a
reduction in size (average 33%) of blood vessels in s.c.
xenograft of EFEMP1c6 vs. U251HF (Figure 2C). The
cell proliferation index in EFEMP1c6 tumors was
approximately 50% of that in U251HF tumors (Figure
2D), suggesting that restricting angiogenesis retards
tumor proliferation and subsequent tumor growth.
Since VEGFA is a dominant pro-angiogenic factor
driving GBM angiogenesis, we quantified VEGFA
mRNA in s.c. tumors and found a significantly lower
expression of VEGFA in EFEMPc6-derived tumors com-
pared to those from U251HF. In contrast, the expression
of VEGFA receptor gene (KDR) was significantly higher
in EFEMP1c6-derived tumor compared that of U251HF
(Figure 2E). The increase in receptor expression may
suggest a compensatory mechanism to offset the loss of
ligand. The effect of EFEMP1 on the expression level of
KDR and its physiological relevance requires further
exploration.
To determine the degree of VEGFA involvement in
EFEMP1-mediated suppression of glioma-cell growth in
vivo, VEGFA cDNA constructs encoding three VEGFA
isoforms (121, 165 or 189) were transfected in
EFEMP1c6. As shown in Figure 2F, the tumor onset
time (time when the tumor becomes measurable) for all
three VEGFA-transfectants was 17 days, close to that of
the original U251HF at day 12, whereas the tumor onset
time of the lacZ-transfectant is 40 days after implanta-
tion. Although over-expression of ectopic VEGFA was
able to partially rescue the tumor growth from the sup-
pression by EFEMP1, restoration of tumor growth rates
were far from complete. At day 23 after implantation,
the average tumor weight from VEGFA-transfected
EFEMP1c6 was 24-27% of U251HF. Thus suppression of
VEGFA is likely only one of several probable
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Page 5 of 12Figure 2 EFEMP1 suppression of tumorigenicity, in vivo cell proliferation, and VEGFA-induced angiogenesis. A, weights of s.c. xenografts
dissected 24 days after implantation with 5 × 10
6 cells of U251HF and its EFEMP1 transfectants. B, total (THb) hemoglobin concentration and
tissue oxygen saturation (StO2) of s.c. xenografts in live mice by modulated imaging before tumor dissections. C-D, immunofluorescence of
tumor frozen-sections, with CD31 antibody detecting blood vessel density and Ki67 antibody detecting proliferation index after DAPI-
counterstaining of the nuclei. E, real-time qRT-PCR quantification of gene expressions in s.c. tumors above, with mean and SD for 6-9 tumors,
normalized to ACTB. F, tumor growth curve based on tumor volume measurement after s.c. implantation.
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growth and EFEMP1 exhibits some VEGF-independent
anti-tumor effects.
We then further investigated the effect of reducing
EFEMP1 levels (via lentiviral expression of shRNA of
EFEMP1 - shEFEMP1) on glioma cell tumorigenicity.
The results showed that EFEMP1 knock-down in
U251HF cells did not cause significant effects on s.c.
tumor growth (data not shown). This result is most
likely due to a low basal level of EFEMP1. We then
investigated two primary culture lines derived from a
WHO grade IV GBM (GBM16B) and a WHO grade III
anaplastic oligodendroglioma (OG2B), and showed that
EFEMP1 knock-down promoted tumor growth starting
at day 14 after s.c. implantation. This led to a significant
increase of tumor weight at day 28 (Figure 3A and 3B).
Western blot and ELISA analyses of tumor lysates con-
firmed reduction of EFEMP1 protein levels due to shE-
FEMP1 expression. Of interest, reduction of EFEMP1
corresponded with an increase of VEGFA (Figure 3C).
Noticeably, there were also positive correlations between
tumor weight and VEGFA levels for the two primary
tumor lines.
EFEMP1 also targets EGFR and AKT signaling
EFEMP1 contains repeated EGF modules and was
shown to activate AKT signaling via binding to EGFR in
pancreatic carcinoma cells [13]. However, we observed
reductions of total EGFR and phosphorylated AKT
(S473) levels after a 48-hour incubation period in three
different glioma cell lines using the same purified
EFEMP1 protein. As shown in Figure 4A, in the two
PTEN null/mutant human glioma cell lines (U251HF
and SNB19) under serum-free conditions, the suppres-
sive effect of EFEMP1 on AKT phosphorylation was
seen 24 hours after the treatment, while total EGFR
reduction occurred a day later. When culturing cells in
medium containing 5% bovine serum during EFEMP1
treatment, there was no effect of EFEMP1 on EGFR and
AKT phosphorylation (data not shown). For the PTEN
wild-type cell line (LN229), pAKT levels were undetect-
able when cultured in serum-free medium (data not
shown), while EGFR and AKT phosphorylation was sup-
pressed by EFEMP1 with serum present. In comparison,
2 hours of exposure to EGF enhanced AKT phosphory-
lation while reducing EGFR levels (Figure 4B), reflecting
the reported negative-feedback regulation of EGFR [23].
We then screened an antibody array using whole-cell
lysate of U251HF and its EFEMP1 stable transfectant
EFEMP1c6 after a 48-hour serum starvation. EFEMP1
over-expression decreased the phosphorylation levels of
multiple AKT substrates (Figure 4C), which is consistent
with an AKT-suppressive role for EFEMP1. Substrates
affected include FOXO transcription factors (FOXO3
and FOXO4) [24-26] and BCL-2 protein family (BAD,
BCL2, and BCL2L1) [27-29] in which the phosphory-
lated state may ensure glioma cell survival under stress-
ful environments. EFEMP1 also reduced the
phosphorylation of PTK2 (known as FAK), PTK2B
(known as Pyk2) and PTK2 downstream target PXN
(known as Paxillin), which together form the FAK-sig-
naling pathway. FAK has been shown to be upstream of
Figure 3 EFEMP1 knock-down promoted tumorigenicity and VEGFA production by two glioma primary cultures representing tumor
mass cell populations. A, growth curves of s.c. xenograft from implantation of 1 × 10
6 cells of adherent primary cultures of GBM (GBM16B)
and anaplastic oligodendroglioma (OG2B), infected with lentivirus of empty vector or shRNA of EFEMP1 (shEFEMP1). B, weights of above tumors
dissected 28 days after implantation. C, immunoblotting of protein extracts from above s.c. xenografts with EFEMP1 and Actin antibodies (upper
panel), and quantification of VEGFA protein level in tumor by an VEGF-165 immunometric assay in duplicates (bottom panel).
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high grade gliomas [30-32].
Human recombinant EFEMP1 protein suppresses glioma
cell growth in vivo
Based on the suppressive function of human recombi-
nant EFEMP1 on EGFR and AKT signaling activities, we
undertook a study of this protein to see whether it
would be capable of suppressing GBM cell growth in
vivo. There was a significant suppression of tumor
development from EFEMP1 via homogenous mixing
with cells prior to implantation in both s.c. and i.c.
xenograft systems. This effect was also seen when
EFEMP1 protein was administrated circumferentially
around established s.c. xenografts (Figure 5A-B). These
findings after both types of EFEMP1 administration in
vivo are consistent with our in vitro data demonstrating
that that EFEMP1 suppresses intracellular oncogenic
signaling, and is also consistent with a potential
suppressive effect on in vivo angiogenesis by directly tar-
geting endothelial cells [3].
Magnetic resonance imaging (MRI) was utilized for
temporal comparison of i.c. tumor development without
losing survival data. As shown in Figure 5C, the i.c.
tumor size in mice implanted with U251HF cells plus
EFEMP1 was smaller compared to cells plus vehicle.
MRI also revealed differences in i.c. tumor morphologies
between EFEMP1 and vehicle treatment. Consistently
shown in three individual mice per group, the vehicle
group exhibited solid tumors with well-defined bound-
aries, a mass effect with right to left midline shift, and
edema around the tumor. In contrast, the EFEMP1
treatment group exhibited a diffusely infiltrative mass, as
is evident by the presence of edema in the right brain
without a discernible solid tumor.
In respect to the finding shown in Figure 3 that
EFEMP1 knock-down enabled a higher tumorigenicity,
we applied EFEMP1 protein to cells expressing
Figure 4 EFEMP1 suppressed EGFR-AKT signaling. Whole cell lysate of three human glioma cell lines were immunoblotted with EGFR, pAKT
and total AKT antibodies after treatments with EFEMP1 protein or EGF (B) for various time periods and in different conditions. (C), protein array
analysis of cell lysates of EFEMP1-transfected and un-transfected U251HF following a 48-hour serum starvation, showing relative levels of
changes on phosphorylated proteins normalized to the level total proteins.
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5D, EFEMP1 protein treatment was able to antagonize
the tumor promoting effect from EFEMP1 knock-down
in GBM16B. Group averages ± SEs were 47.5 ± 3.6
mm
3 in the vehicle treatment group, compared to only
27.8 ± 2.2 mm
3 in the +10 ng EFEMP1 treatment group
and 22.3 ± 1.7 mm
3 in the +20 ng EFEMP1 treatment
group (P < 0.0001). Tumor doubling times were
increased in a somewhat dose-dependent manner, being
3.14 ± 0.23 days with vehicle, 3.55 ± 0.31 days with +10
Figure 5 Human recombinant EFEMP1 protein is able to suppress glioma xenograft growth. A, weight of s.c. xenografts dissected 28 days
after implantation of U251HF cells (1 × 10
6) mixed with EFEMP1 protein (20 ng) or vehicle prior implantation, or peri-tumoral injection with
EFEMP1 (10 ng × 2 sides) or vehicle 1 week after implantation and a repeat of EFEMP1 treatment in the following week. Mean (SD) are based
on 4 tumors with treatments per group. B, Kaplan-Meier survival curves for mice after i.c. implantation with U251HF cells (1 × 10
5) mixed with 4
ng EFEMP1 protein or same volume of vehicle. C, T2-weighted images of mice from vehicle and EFEMP1-treatment groups 32 days after
implantation. D, s.c. xenograft growth curve after implantation with the same amount of GBM16B expressing shEFEMP1, mixed with the same
volume of EFEMP1 or vehicle prior implantation. Symbols (error bars) on the curves represent averages (SDs) of tumor volumes based on
longitudinal data from 8 or 9 tumors per group that was log-transformed to stabilize variances for the repeated-measures ANOVA. P < 0.001 for
the test of any separation between curves among all three groups, and P = 0.046 for the test of any difference in growth rates among all three
groups.
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EFEMP1 (P = 0.046).
Discussion
T h eo v e r a l lr e s u l t so ft h i ss t u d yr e v e a l e dar o l ef o r
EFEMP1 in the suppression of glioma growth, via inde-
pendent blockade of EGFR and AKT signaling pathways
and the repression of VEGFA-induced angiogenesis.
Activation of these molecular pathways is a well-known
molecular-pathological feature of GBM. The finding of a
favorable clinical prognosis effect from EFEMP1 expres-
sion in GBM patients is consistent with these laboratory
findings. EFEMP1 anti-angiogenic effects appear to take
place through both VEGFA-dependent and VEGFA-
independent mechanisms. EFEMP1-mediated suppres-
sion of glioma-cell expression of VEGFA would result in
the suppression of VEGFA stimulation of angiogenesis,
which is in addition to EFEMP1’s direct inhibition of
endothelial cells sprouting [3].
In addition to the overall improvement of mouse sur-
vival resulting from EFEMP1 over-expression, MRI data
of i.c. glioma morphologies revealed EFEMP1’s function
in potentiating glioma-cell infiltration, as shown by in
vitro studies [14]. This is the first demonstration of
EFEMP1’s role in the regulation of glioma cell invasion
in an i.c. xenograft system. In our GBM cell line/pri-
mary culture in vivo systems, the tumor-suppressive
effect of EFEMP1 overwhelmed its pro-invasive activity.
Further investigation is needed to understand the mole-
cular context of EFEMP1 in control of different malig-
nant behaviors of cancer cells.
This study showed that EFEMP1 repressed AKT activ-
ity and phosphorylation of multiple AKT substrates in
human malignant glioma cells. These results differed
from observations in pancreatic adenocarcinoma cells,
where EFEMP1 enhanced AKT phosphorylation [13],
but were in accordance with findings in nasopharyngeal
carcinomas cells, where EFEMP1 suppressed AKT phos-
phorylation. Such discrepancies may be related to differ-
ent membrane receptors and downstream signaling
pathways given the plethora of molecular and cellular
abnormalities in different cancer cell types.
EGFR amplification occurs in 40 to 70% of primary
GBMs, but is not observed in lower-grade astrocytomas
[33]. Activation of EGFR and PI3K/AKT signaling path-
ways are clearly the causes of malignant behavior of
GBM and emerges as common pathways regulating cel-
lular proliferation, survival, migration and invasion [34].
Our data revealed the negative regulation of EGFR by
EFEMP1, via down-regulation of total EGFR levels. It is
well-documented that receptor activation by EGF leads
to the internalization and degradation of EGFR [35].
The EFEMP1-initiated reduction of total EGFR,
although not as quick as EGF-initiated negative-feedback
regulation of EGFR, could involve a similar protein-
degradation mechanism, since EGFR mRNA levels were
not reduced upon EFEMP1 treatment.
We have shown that EFEMP1-mediated down-regula-
tion of AKT signaling occurs in PTEN null/mutant
glioma cells under serum-starvation conditions but not
in serum-containing medium. This is consistent with
the lack of an EFEMP1-mediated effect on cell prolifera-
tion in serum-containing culture medium, in contrast to
the dramatic suppression of tumor formation in both s.
c. and i.c. xenograft systems. Our data revealed that
EFEMP1 suppresses tumor growth via multiple mechan-
isms. In addition to the aforementioned effect on
attenuating EGFR/AKT signaling activities, we demon-
strate EFEMP1 involvement in regulation of the tumor
microenvironment through down-regulation of glioma-
cell VEGFA production. The mechanism of EFEMP1 in
the down-regulation of VEGFA expression is not clari-
fied by this study, though it could be an indirect effect
from inhibition of AKT signaling [36].
Current anti-angiogenic agents such as bevacizumab, a
humanized VEGFA antibody, have met with limited suc-
cess in glioma patients due to its promoting cell inva-
sion [37, 38]. Either EGFR-targeting monoclonal
antibody or inhibition of tyrosine kinases activity in
glioma patients produced minimal tumor response and
no improvement in overall survival [39, 40]. The identi-
fication for EFEMP1 of a VEGFA-independent mechan-
ism in addition to its VEGFA-dependent mechanism in
suppressing angiogenesis and EFGR- and AKT-signaling
activities suggests that it may be possible to develop
additional anti-angiogenic agents that are complemen-
tary to bevacizamab, or potentially still effective in the
face of bevacizumab resistance. While more studies are
needed to further define the role of EFEMP1 (i.e. anti-
angiogenic vs. pro-invasive), results from this study pro-
vide a mechanistic rationale on developing EFEMP1, or
EFEMP1-derived signaling peptide, as a new potent
therapy for patients with high-grade gliomas.
In reviewing published studies on EFEMP1 in cancer
a n di n c o r p o r a t i n gr e s u l t sf r o mt h i ss t u d y ,i ts h o u l db e
noted that EFEMP1’s function, whether promoting or
inhibiting cancer growth, may be dependent on a mole-
cular context that differs by cancer cell type and malig-
nancy stage. The identification of proteins that are
cooperative with EFEMP1 in the regulation of intracellu-
lar signaling pathways and the tumor microenvironment
would distinguish the differential effect of EFEMP1 in
cancer. The tumor-suppressive effect of EFEMP1 to
glioma cells may also be applicable to other cancer
types that have hyperactivation of EGFR and AKT sig-
naling pathways. Some of thesea r el u n g ,l i v e r ,b r e a s t ,
and prostate cancers, where EFEMP1 promoter methyla-
tion and/or expression were down-regulated [4-8].
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Our data revealed that EFEMP1 is a favorable prognos-
tic factor for GBM, has a tumor-suppressive effect in
malignant glioma cells, and acts in the extracellular
compartment via independent blocking of EGFR and
AKT signaling pathways while also repressing VEGFA-
induced angiogenesis. Results of these findings justify
therapeutic development of EFEMP1-derived agents for
GBM. In addition, the discovery of the function of
EFEMP1 as a tumor suppressor that modulates EGFR
suggests a need to further investigate EFEMP1 as a
potential predictive marker for anti-EGFR therapies of
cancer, including glioblastoma, lung, breast, prostate,
and liver cancers.
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